AR114471A1 - Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en células vero y composición de vacuna que la comprende - Google Patents
Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en células vero y composición de vacuna que la comprendeInfo
- Publication number
- AR114471A1 AR114471A1 ARP190100906A ARP190100906A AR114471A1 AR 114471 A1 AR114471 A1 AR 114471A1 AR P190100906 A ARP190100906 A AR P190100906A AR P190100906 A ARP190100906 A AR P190100906A AR 114471 A1 AR114471 A1 AR 114471A1
- Authority
- AR
- Argentina
- Prior art keywords
- yellow fever
- fever virus
- live attenuated
- vero cells
- virus strain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/08—Inactivation or attenuation by serial passage of virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24164—Methods of inactivation or attenuation by serial passage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se refiere a una cepa del virus de la fiebre amarilla viva atenuada adaptada para crecer en células Vero a partir de una subcepa del virus de la fiebre amarilla 17D parental que no está adaptada para crecer en células Vero, donde dicha cepa del virus de la fiebre amarilla viva atenuada es menos neurovirulenta que dicha subcepa del virus de la fiebre amarilla 17D parental.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18305405.5A EP3549603A1 (en) | 2018-04-06 | 2018-04-06 | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114471A1 true AR114471A1 (es) | 2020-09-09 |
Family
ID=62046805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190100906A AR114471A1 (es) | 2018-04-06 | 2019-04-05 | Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en células vero y composición de vacuna que la comprende |
Country Status (15)
Country | Link |
---|---|
US (2) | US11471521B2 (es) |
EP (2) | EP3549603A1 (es) |
JP (1) | JP7370338B2 (es) |
KR (1) | KR20200140292A (es) |
CN (1) | CN111918669A (es) |
AR (1) | AR114471A1 (es) |
AU (1) | AU2019249329A1 (es) |
BR (1) | BR112020018879A2 (es) |
CA (1) | CA3095438A1 (es) |
CO (1) | CO2020011984A2 (es) |
PE (1) | PE20210317A1 (es) |
SG (1) | SG11202009439YA (es) |
TW (1) | TWI835787B (es) |
WO (1) | WO2019192997A1 (es) |
ZA (1) | ZA202006280B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3549603A1 (en) | 2018-04-06 | 2019-10-09 | Sanofi Pasteur | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2716399C (en) | 2008-03-05 | 2020-07-21 | Pierre Chouvenc | Process for stabilizing an adjuvant containing vaccine composition |
ES2524975T3 (es) * | 2009-07-31 | 2014-12-16 | Ge Healthcare Bio-Sciences Corp. | Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células |
AR079970A1 (es) * | 2010-07-23 | 2012-02-29 | Xcellerex Inc | Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas |
EP2877208B1 (en) | 2012-07-24 | 2021-05-12 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
EP3549603A1 (en) * | 2018-04-06 | 2019-10-09 | Sanofi Pasteur | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
-
2018
- 2018-04-06 EP EP18305405.5A patent/EP3549603A1/en not_active Withdrawn
-
2019
- 2019-04-02 EP EP19714666.5A patent/EP3773701A1/en active Pending
- 2019-04-02 BR BR112020018879-4A patent/BR112020018879A2/pt unknown
- 2019-04-02 JP JP2020554449A patent/JP7370338B2/ja active Active
- 2019-04-02 TW TW108111634A patent/TWI835787B/zh active
- 2019-04-02 CN CN201980023339.4A patent/CN111918669A/zh active Pending
- 2019-04-02 KR KR1020207030059A patent/KR20200140292A/ko not_active Application Discontinuation
- 2019-04-02 PE PE2020001491A patent/PE20210317A1/es unknown
- 2019-04-02 CA CA3095438A patent/CA3095438A1/en active Pending
- 2019-04-02 WO PCT/EP2019/058268 patent/WO2019192997A1/en unknown
- 2019-04-02 US US17/045,322 patent/US11471521B2/en active Active
- 2019-04-02 SG SG11202009439YA patent/SG11202009439YA/en unknown
- 2019-04-02 AU AU2019249329A patent/AU2019249329A1/en active Pending
- 2019-04-05 AR ARP190100906A patent/AR114471A1/es unknown
-
2020
- 2020-09-28 CO CONC2020/0011984A patent/CO2020011984A2/es unknown
- 2020-10-09 ZA ZA2020/06280A patent/ZA202006280B/en unknown
-
2021
- 2021-11-05 US US17/453,758 patent/US11452772B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11452772B2 (en) | 2022-09-27 |
US11471521B2 (en) | 2022-10-18 |
CO2020011984A2 (es) | 2021-02-08 |
KR20200140292A (ko) | 2020-12-15 |
AU2019249329A1 (en) | 2020-12-03 |
CA3095438A1 (en) | 2019-10-10 |
JP7370338B2 (ja) | 2023-10-27 |
US20220047692A1 (en) | 2022-02-17 |
PE20210317A1 (es) | 2021-02-16 |
EP3549603A1 (en) | 2019-10-09 |
TW202003028A (zh) | 2020-01-16 |
EP3773701A1 (en) | 2021-02-17 |
BR112020018879A2 (pt) | 2021-01-26 |
SG11202009439YA (en) | 2020-10-29 |
TWI835787B (zh) | 2024-03-21 |
RU2020136260A (ru) | 2022-05-06 |
WO2019192997A1 (en) | 2019-10-10 |
JP2021520384A (ja) | 2021-08-19 |
CN111918669A (zh) | 2020-11-10 |
ZA202006280B (en) | 2022-06-29 |
US20210154289A1 (en) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201800108A1 (ru) | Вакцинные композиции для профилактики абровирусных инфекций | |
UY37252A (es) | Compuestos para el tratamiento de infección por virus de la hepatitis b | |
UY37581A (es) | Compuestos para el tratamiento de la infección por virus de la hepatitis b | |
CO2017004119A2 (es) | Partículas tipo virus modificadas de cmv | |
MY194449A (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
MX2020005554A (es) | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. | |
AR102658A1 (es) | Composición para el tratamiento de telas | |
CU24510B1 (es) | Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes | |
AR106026A1 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
CU24579B1 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
MX2017016896A (es) | Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos. | |
CU24682B1 (es) | Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivados | |
PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
WO2016100615A3 (en) | Methods and composition for neutralization of influenza | |
AR114471A1 (es) | Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en células vero y composición de vacuna que la comprende | |
BR112018074910A2 (pt) | composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito | |
PE20190225A1 (es) | Un metodo para reducir la contaminacion de huevo | |
AR115070A1 (es) | Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso | |
CL2021003447A1 (es) | Virus para vacuna contra el síndrome respiratorio y reproductivo porcino | |
AR117942A1 (es) | Vacunas contra el zika, composiciones inmunogénicas y métodos que las utilizan | |
MX2018003173A (es) | Vacunas de salmonella choleraesuis-salmonella typhimurium. | |
PE20220119A1 (es) | Control del craqueo al vapor para mejorar el pci de los pellets negros | |
AR095118A1 (es) | Un procedimiento de inactivación viral en composición que comprende factor vii |